Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Hemodynamic regulation of perivalvular endothelial gene expression prevents deep venous thrombosis
John D. Welsh, … , Juan M. Jimenez, Mark L. Kahn
John D. Welsh, … , Juan M. Jimenez, Mark L. Kahn
Published November 11, 2019
Citation Information: J Clin Invest. 2019;129(12):5489-5500. https://doi.org/10.1172/JCI124791.
View: Text | PDF
Research Article Vascular biology Article has an altmetric score of 13

Hemodynamic regulation of perivalvular endothelial gene expression prevents deep venous thrombosis

  • Text
  • PDF
Abstract

Deep venous thrombosis (DVT) and secondary pulmonary embolism cause approximately 100,000 deaths per year in the United States. Physical immobility is the most significant risk factor for DVT, but a molecular and cellular basis for this link has not been defined. We found that the endothelial cells surrounding the venous valve, where DVTs originate, express high levels of FOXC2 and PROX1, transcription factors known to be activated by oscillatory shear stress. The perivalvular venous endothelial cells exhibited a powerful antithrombotic phenotype characterized by low levels of the prothrombotic proteins vWF, P-selectin, and ICAM1 and high levels of the antithrombotic proteins thrombomodulin (THBD), endothelial protein C receptor (EPCR), and tissue factor pathway inhibitor (TFPI). The perivalvular antithrombotic phenotype was lost following genetic deletion of FOXC2 or femoral artery ligation to reduce venous flow in mice, and at the site of origin of human DVT associated with fatal pulmonary embolism. Oscillatory blood flow was detected at perivalvular sites in human veins following muscular activity, but not in the immobile state or after activation of an intermittent compression device designed to prevent DVT. These findings support a mechanism of DVT pathogenesis in which loss of muscular activity results in loss of oscillatory shear–dependent transcriptional and antithrombotic phenotypes in perivalvular venous endothelial cells, and suggest that prevention of DVT and pulmonary embolism may be improved by mechanical devices specifically designed to restore perivalvular oscillatory flow.

Authors

John D. Welsh, Mark H. Hoofnagle, Sharika Bamezai, Michael Oxendine, Lillian Lim, Joshua D. Hall, Jisheng Yang, Susan Schultz, James Douglas Engel, Tsutomu Kume, Guillermo Oliver, Juan M. Jimenez, Mark L. Kahn

×

Figure 1

FOXC2- and PROX1-expressing endothelial cells around the venous valve exhibit a strong antithrombotic phenotype.

Options: View larger image (or click on image) Download as PowerPoint
FOXC2- and PROX1-expressing endothelial cells around the venous valve ex...
(A) Schematic illustration of mouse venous valve sections defining the regions of luminal endothelium (Lumen endo), valve leaflet endothelium (Valve endo), and valve sinus endothelium (Sinus endo). (B) FOXC2 and PROX1 were measured using anti-FOXC2 and anti-GFP immunostaining of wild-type and PROX1-GFP transgenic mice. Cell nuclei were detected with DAPI staining. White dashed lines indicate luminal venous endothelial cells; green dashed lines indicate perivalvular endothelial cells. Arrows indicate the direction of venous blood flow. Images are representative of 8 separate experiments using different animals. (C–F) Mouse saphenous veins were immunostained to detect expression of vWF (n = 8 valves), THBD (n = 9), EPCR (n = 8), and TFPI (n = 13). Relative quantitation of staining in luminal (L), valvular (V), and sinus (S) endothelial cells is shown at right for each protein. (G and H) Mouse saphenous veins were immunostained to detect expression of the adhesion proteins ICAM1 (n = 7) and P-selectin (n = 7). Relative quantitation of protein levels is shown at right for each protein. (I) P-selectin is not expressed on the surface of perivalvular endothelial cells. Surface P-selectin was detected by i.v. injection of Alexa Fluor 647–labeled anti–P-selectin antibodies into PROX1-GFP transgenic animals. Images are representative of 6 separate experiments in 4 mice. White dashed lines indicate luminal venous endothelial cells, and green dashed lines indicate perivalvular endothelial cells. Arrows indicate the direction of venous blood flow. For each graph the mean is shown as the bar with dots representing each data point, and error bars indicate SD. Significance was determined by ratio paired t test and corrected for multiple comparisons. *P < 0.025; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 13 X users
Referenced in 1 patents
Highlighted by 1 platforms
47 readers on Mendeley
See more details